660838-05-1

Basic information

• Product Name: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER;5-(Boc-aMino)-2-Methylaniline
• CAS NO: 660838-05-1
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Mol File: 660838-05-1.mol

Chemical Properties

• Boiling Point: 308.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 13.57±0.70(Predicted)
• CAS DataBase Reference: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(660838-05-1)
• EPA Substance Registry System: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(660838-05-1)

Safety Data

• Hazardous Substances Data: 660838-05-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of various pharmaceuticals. It aids in the development of new drugs by protecting amines during the synthesis process, ensuring the successful formation of the desired compounds.
Used in Agrochemical Industry:
(3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of various agrochemicals, including pesticides. Its protective role in organic synthesis helps in the creation of effective and safe pesticides for agricultural applications.
Used in Organic Synthesis:
(3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a protecting agent for amines during organic synthesis. It helps prevent unwanted side reactions, allowing chemists to focus on the desired reactions and achieve the target compounds with higher yields and purity.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 95-80-7 4-methylbenzene-1,3-diamine 
• 2458-12-0 3-amino-p-toluic acid 
• 630410-29-6 (4-methyl-3-nitro-phenyl)-carbamic acid tert-butyl ester 
• 119-32-4 4-Methyl-3-nitroanilin 

Downstream Products

• 872092-02-9 tert-butyl [3-(8-methoxy-4-oxoquinazolin-3(4H)-yl)-4-methylphenyl]carbamate 
• 884000-87-7 tert-butyl {4-methyl-3-[(quinoxalin-6-ylcarbonyl)amino]phenyl}carbamate 
• 878745-39-2 tert-butyl 4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenylcarbamate 
• 946422-07-7 (3-{3-[6-(2,4-dimethoxy-benzylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-4-methyl-phenyl)carbamic acid tert-butyl ester 
• 946422-15-7 [4-methyl-3-(6-methylsulfanyl-[4,5']bipyrimidinyl-4'-ylamino)-phenyl]-carbamic acid tert-butyl ester 
• 1024583-35-4 (3-{[2-(3-ethyl-ureido)-benzothiazole-6-carbonyl]-amino}-4-methyl-phenyl)-carbamic acid tert-butyl ester 
• 1172621-17-8 tert-butyl 3-(2-(dimethylamino)acetamido)-4-mehtylphenylcarbamate 
• 1301267-30-0 tert-butyl 4-methyl-3-(3-phenylureido)phenylcarbamate 
• 1172621-18-9 tert-butyl 3-(2-(1,3-dioxoisoindolin-2-yl)acetamido)-4-methylphenylcarbamate 
• 1172621-34-9 methyl 2-(5-(tert-butoxycarbonylamino)-2-methylphenylamino)-2-oxoacetate 
• 1202759-64-5 C₂₄H₂₉N₅O₂ 
• 1318243-02-5 t-butyl 3-(4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamido)-4-methylphenylcarbamate 
• 1318243-03-6 N-(5-amino-2-methylphenyl)-4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1351237-52-9 N-(5-(3-(3-(2-cyanopropan-2-yl)phenyl)ureido)-2-methylphenyl)thieno[2,3-b]pyrazine-6-carboxamide 

Relevant articles and documents

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia

Starting from a dihydropyrimidopyrimidine core scaffold based compound 27 (GNF-7), we discovered a highly potent (ABL1: IC50 of 70 nM) and selective (S score (1) = 0.02) BCR-ABL inhibitor 18a (CHMFL-ABL-053). Compound 18a did not exhibit apparent inhibitory activity against c-KIT kinase, which is the common target of currently clinically used BCR-ABL inhibitors. Through significant suppression of the BCR-ABL autophosphorylation (EC50 about 100 nM) and downstream mediators such as STAT5, Crkl, and ERK's phosphorylation, 18a inhibited the proliferation of CML cell lines K562 (GI50 = 14 nM), KU812 (GI50 = 25 nM), and MEG-01 (GI50 = 16 nM). A pharmacokinetic study revealed that 18a had over 4 h of half-life and 24% bioavailability in rats. A 50 mg/kg/day dosage treatment could almost completely suppress tumor progression in the K562 cells inoculated xenograft mouse model. As a potential useful drug candidate for CML, 18a is under extensive preclinical safety evaluation now.

FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1

The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by

4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by

PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS

The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.

Synthesis of amino-substituted indoles using the Bartoli reaction

We report herein the concise preparation of a range of functionalised aminoindoles via a new application of the Bartoli reaction. Scope and limitations of the methodology have been extensively studied to reveal the importance of protecting groups and subs

Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives

Our aim was to discover RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors that possess strong activity and sufficient oral absorption, and thus, we selected a 5-amino-linked thiazolo[5,4-d]pyrimidine derivative as the lead compound because of its potential kinase inhibitory activities and its desired solubility. The novel tertiary 1-cyano-1-methylethoxy substituent was designed to occupy the hydrophobic region of 'back pocket' of BRAF on the basis of the X-ray co-crystal structure data of BRAF. In addition, we found that N-methylation of the amine linker could control the twisted molecular conformation leading to improved solubility. These approaches produced N-methyl thiazolo[5,4-b]pyridine-5-amine derivative 5. To maximize the in vivo efficacy, we attempted salt formation of 5. Our result indicated that the besylate monohydrate salt form (5c) showed significant improvement of both solubility and oral absorption. Owing to the improved physicochemical properties, compound 5c demonstrated regressive antitumor efficacy in a HT-29 xenograft model.

Affinity-based probes based on type II kinase inhibitors

Protein kinases are key components of most mammalian signal transduction networks and are therapeutically relevant drug targets. Efforts to study protein kinase function would benefit from new technologies that are able to profile kinases in complex prote